247 filings
Page 9 of 13
8-K
lh0e53xe
26 Aug 22
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance
4:37pm
8-K/A
sg4skiv1s4c 4kw0t4
24 Aug 22
Changes in Registrant's Certifying Accountant
5:15pm
424B3
dbke3ae
22 Aug 22
Prospectus supplement
5:13pm
8-K
1ot4zkgz8dcr8r24zdk
22 Aug 22
Results of Operations and Financial Condition
5:08pm
8-K
5y6d4z
16 Aug 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:01pm
NT 10-Q
snkob7q5qascjcay
15 Aug 22
Notice of late quarterly filing
5:59pm
424B3
jrm47oox
12 Aug 22
Prospectus supplement
5:30pm
8-K
xpl8hjkq4gmei8m
12 Aug 22
Entry into a Material Definitive Agreement
5:04pm
424B3
qkvpkuvbc6ejp n1
2 Aug 22
Prospectus supplement
9:35am
8-K
ec35wm6 2iq
2 Aug 22
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
9:33am
424B3
llikemp4hetj8ont
11 Jul 22
Prospectus supplement
5:16pm
8-K
7msvrw4oxlxqel
11 Jul 22
Departure of Directors or Certain Officers
4:05pm
424B3
6fxkxp47oa3c3layp2
30 Jun 22
Prospectus supplement
6:34am
8-K
2hutx28qlwzfucj1jc3
29 Jun 22
Allarity Therapeutics Announces Executive Leadership Transition
7:44pm
8-K
uftu5r711d0wuicxx
10 Jun 22
Entry into a Material Definitive Agreement
4:01pm
424B3
c425hfsc
7 Jun 22
Prospectus supplement
5:26pm
EFFECT
tlmmm
7 Jun 22
Notice of effectiveness
12:15am
POS AM
drzraeqjpl2ee2m hbld
2 Jun 22
Prospectus update (post-effective amendment)
7:58pm
8-K
kcul1
27 May 22
Allarity Therapeutics Reports First Quarter 2022 Financial Results
5:29pm